Ascendis Pharma Endocrinology Division A/S

CVR 32323537 · Public limited company (A/S) · Active · Low risk

Ascendis Pharma Endocrinology Division A/S is a Public limited company (A/S), founded on , based in Hellerup. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 0.5% over the next 12 months, which is 0.4 times the average for Danish companies. 14 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -935.7m and a net result of DKK -38.8m.

Bankruptcy risk for Ascendis Pharma Endocrinology Division A/S

0.5%
probability of bankruptcy within 12 months
Low risk

0.4 × the average (1.41%) · higher risk than 60% of active Danish companies

Lowest riskHighest risk

Increases the risk

Equity ratio< -50% · bankruptcy rate 19.3%2.2×
Negative equityYes · bankruptcy rate 17.5%2.0×
Equity vs. share capital< 0× · bankruptcy rate 17.3%2.0×
Return on assets< -20% · bankruptcy rate 16.7%1.9×
Going-concern uncertaintyYes · bankruptcy rate 16.3%1.9×
Number of CEOs0 · bankruptcy rate 12.7%1.4×
CEOs in total (historical)0 · bankruptcy rate 12.4%1.4×
RegionHovedstaden · bankruptcy rate 11.6%1.3×

Reduces the risk

Reporting classReporting class C, large enterprise · bankruptcy rate 0.2%0.03×
Published annual reports10+ · bankruptcy rate 3.0%0.35×
Time at current address5+ yrs · bankruptcy rate 3.1%0.35×
Age (years)10–20 yrs · bankruptcy rate 3.9%0.45×
Company typeA/S · bankruptcy rate 4.4%0.50×
Auditor registered in CVRYes · bankruptcy rate 4.8%0.55×
Audit opted outNo · bankruptcy rate 4.8%0.55×
Share of late annual reports< 0.01% · bankruptcy rate 5.2%0.59×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
32323537
Status
Active
Company type
Public limited company (A/S)
Founded
(14 years)
Address
c/o Ascendis Pharma A/S, Tuborg Boulevard 12
2900 Hellerup
Municipality
Gentofte
Industry
Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Ikke-finansielle holdingselskaber
Share capital
DKK 1.0m
Auditor
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB
Audit opted out
No

Warning signs

Annual reports filed late0 of 14
Missing annual reportNo
Negative equityYes
Equity ratio-1,197.3%
Current ratio15%
Moves (last 2 years)0
CEO changes in total0
CEO's previous bankruptcies0
Other companies at the address224
Going-concern uncertaintyYes

Financials and key figures

Financial year202520242023
RevenueDKK 140.8mDKK 122.9mDKK 157.4m
Gross profitDKK 67.2mDKK 82.9mDKK 103.1m
Net profitDKK -38.8mDKK -121.1mDKK -60.9m
EquityDKK -935.7mDKK -896.8mDKK -775.7m
Total assetsDKK 78.1mDKK 25.3mDKK 102.2m
CashDKK 2,000DKK 39k–
Short-term debtDKK 28.6mDKK 15.8m–
Avg. employees00–

Latest annual report: Reporting class C, large enterprise · auditor's statement: Auditor's report on audited financial statements · Deloitte Statsautoriseret Revisionspartnerselskab.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 202590
1 Jan 2024 – 31 Dec 2024126
1 Jan 2023 – 31 Dec 2023172
1 Jan 2022 – 31 Dec 202283
1 Jan 2021 – 31 Dec 2021129
1 Jan 2020 – 31 Dec 202088
1 Jan 2019 – 31 Dec 2019132
1 Jan 2018 – 31 Dec 2018142
1 Jan 2017 – 31 Dec 2017138
1 Jan 2016 – 31 Dec 2016131
1 Jan 2015 – 31 Dec 2015130
1 Jan 2014 – 31 Dec 2014133
1 Jan 2013 – 31 Dec 2013154
29 Jun 2012 – 31 Dec 2012154

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
BoardMichael Wolff JensenCurrent
BoardJan Møller MikkelsenCurrent
BoardAnni Lotte Kirstine PedersenCurrent
Owner (100%)ASCENDIS PHARMA A/SCurrent
AuditorDELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKABCurrent
FounderASCENDIS PHARMA A/SCurrent

Address history (2 moves)

c/o Ascendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup
c/o Ascendis Pharma A/S, Tuborg Boulevard 5, 2900 Hellerup
c/o Ascendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup

Former names

Ascendis Pharma Endocrinology Division A/S – now
ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S –
ACP 30.06.2012 2 A/S –

Other companies at the same address

Similar companies in Gentofte

Questions and answers about Ascendis Pharma Endocrinology Division A/S

Has Ascendis Pharma Endocrinology Division A/S gone bankrupt?

No, Ascendis Pharma Endocrinology Division A/S is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Ascendis Pharma Endocrinology Division A/S?

Our model estimates a bankruptcy risk of 0.5% over the next 12 months (low risk), which is 0.4 times the average for Danish companies.

Who is the auditor of Ascendis Pharma Endocrinology Division A/S?

Ascendis Pharma Endocrinology Division A/S most recently used DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB.

When was Ascendis Pharma Endocrinology Division A/S founded?

Ascendis Pharma Endocrinology Division A/S was founded on 29 June 2012.

What is the equity of Ascendis Pharma Endocrinology Division A/S?

Equity was DKK -935.7m according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.